A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Copper Lowering Therapy With Tetrathiomolybdate as an Antiangiogenic Strategy in Cancer

By  

Current Cancer Drug Targets, Vol. 5, Iss. 3, 2005-05 ,pp. : 195-202

Bentham Science Publishers

Access to resources Recommend Favorite

Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

By >   Pietrantonio Filippo   Martinetti Antonia   Buzzoni Roberto   Gevorgyan Arpine   Bajetta Emilio  

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan cost effective in metastatic colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite